A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

激活西妥昔单抗杀死 K-RAS 突变结直肠肿瘤的小分子

• 批准号: 8647920
• 负责人: WILLIAM W BACHOVCHIN
• 金额: $ 14.7万
• 依托单位: ARISAPH PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-24 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8647920
• 关键词: Accounting; Activated Natural Killer Cell; Adjuvant Therapy; Affect; Antibodies; Antigen Targeting; Binding; Biological Assay; Cancer Etiology; Cancer Patient; Cancer cell line; Cells; Cessation of life; Cetuximab; Chronic Lymphocytic Leukemia; Clinical; Colon Carcinoma; Colorectal Cancer; Colorectal Neoplasms; Disease; Dose; Early treatment; Effector Cell; Enhancing Antibodies; Epidermal Growth Factor; Epidermal Growth Factor Receptor; Extracellular Domain; FDA approved; Family; Fc Receptor; Growth; Histology; Human; IgG1; Immune; Immunoglobulin G; Immunotherapeutic agent; Infiltration; Investigational Therapies; KRAS2 gene; Killer Cells; Lead; Malignant Neoplasms; Measures; Mediating; Modeling; Mus; Mutation; Natural Killer Cells; Non-Hodgkin' s Lymphoma; Nude Mice; Oncogenes; Operative Surgical Procedures; Patients; Peptide Hydrolases; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Production; Receptor Signaling; Rectal Cancer; Reporting; Resistance; Safety; Signal Transduction; Small Business Technology Transfer Research; Staging; Testing; Toxic effect; Trastuzumab; Tumor Antibodies; United States; Up-Regulation; Xenograft procedure; advanced disease; analog; antibody-dependent cell cytotoxicity; anticancer activity; arm; base; chemokine; chemotherapy; chimeric antibody; cytokine; drug candidate; improved; in vivo; inhibitor/antagonist; irinotecan; killings; metastatic colorectal; mortality; mouse model; mutant; neoplastic cell; novel therapeutic intervention; outcome forecast; oxaliplatin; panitumumab; phase 1 study; phase 2 study; response; rituximab; small molecule; tumor; tumor growth; tumor microenvironment

In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introduction of irinotecan, oxaliplatin and targeted agents. The latter include the antibodies, cetuximab and panitumumab, initially approved by the FDA for patients who fail chemotherapy. The antibodies were selected for their ability to kill tumors by blockade of the epidermal growth factor receptor (EGFR). How- ever, although the anti-EGFR antibodies promised efficacy with reduced toxicity compared to chemotherapy, less than 12% of CRC patients respond to the antibodies as single agents. Resistance is largely due to mutations that activate the KRAS oncogene to drive CRC growth independently of EGFR signaling. The FDA has restricted cetuximab and panitumumab to treatment of metastatic CRC that expresses non-mutated KRAS. A new therapeutic approach in CRC might be to exploit an alternative mechanism of action for cetuximab called antibody-dependent cellular cytotoxicity (ADCC). Cetuximab can potentially engage innate killer cells (K cells) to kill tumor cells by ADCC, regardless of whether or not the tumor has the KRAS mutation. However, when cetuximab is used as a single agent, little clinical benefit appears to come from ADCC. One way to improve the impact of ADCC would be to combine cetuximab with an agent that can enhance the efficiency of tumor killing by K cells. ARI-4175 has been selected for this purpose because preliminary results suggest it can stimulate cetuximab-mediated ADCC to produce tumor responses in KRAS mutant CRC in mice. The Specific Aim is to demonstrate that ARI-4175 can amplify cetuximab-mediated ADCC to produce significant tumor responses in nude mice challenged with a human KRAS mutant CRC cell line (HCT-116) that is resistant to cetuximab as a single agent. Tumor responses to treatment will be measured, tumor attack by K cells will be assessed by histology and immunostaining of responsive tumors, and the effect of experimental therapy on ADCC will be assayed ex vivo. The approach will seek to substantiate preliminary evidence suggesting that ARI-4175 activates a particular type of K cell-the natural killer (NK) cell-to kill tumors by ADCC. For ARI-4175 to be a viable drug candidate it must interact with cetuximab to produce significant tumor responses in the HCT-116 model with evidence of an immune mechanism of action. If the STTR Phase I study is successful, IND-enabling studies and the initiation of a phase 1 clinical trial of ARI-4175 will be proposed for STTR Phase II.

在美国，结直肠癌（CRC）是癌症死亡的第三大原因。手术是早期结直肠癌的主要治疗方法，但在晚期疾病中通常需要辅助治疗。大约55%的CRC患者患有转移性疾病，尽管由于引入伊立替康、奥沙利铂和靶向药物而逐渐改善，但预后不良。后者包括抗体，西妥昔单抗和帕尼单抗，最初由FDA批准用于化疗失败的患者。选择抗体是因为它们通过阻断表皮生长因子受体（EGFR）杀死肿瘤的能力。然而，尽管与化疗相比，抗EGFR抗体承诺具有降低的毒性的功效，但少于12%的CRC患者对作为单一药剂的抗体有反应。耐药主要是由于激活KRAS癌基因的突变，以独立于EGFR信号传导驱动CRC生长。FDA限制西妥昔单抗和帕尼单抗治疗表达非突变KRAS的转移性CRC。 CRC的一种新的治疗方法可能是利用西妥昔单抗的另一种作用机制，称为抗体依赖性细胞毒性（ADCC）。西妥昔单抗可以通过ADCC潜在地参与先天性杀伤细胞（K细胞）杀死肿瘤细胞，无论肿瘤是否具有KRAS突变。然而，当西妥昔单抗作为单一药物使用时，ADCC似乎没有多少临床益处。改善ADCC影响的一种方法是将联合收割机西妥昔单抗与能够增强K细胞杀伤肿瘤效率的药物联合使用。ARI-4175已被选择用于此目的，因为初步结果表明它可以刺激西妥昔单抗介导的ADCC在小鼠的KRAS突变CRC中产生肿瘤应答。具体目的是证明ARI-4175可以扩增西妥昔单抗介导的ADCC，从而在用对西妥昔单抗单药耐药的人KRAS突变CRC细胞系（HCT-116）攻击的裸鼠中产生显著的肿瘤应答。将测量肿瘤对治疗的反应，将通过组织学和反应性肿瘤的免疫染色评估NK细胞的肿瘤攻击，并将离体测定实验治疗对ADCC的影响。该方法将寻求证实初步证据，表明ARI-4175激活一种特定类型的K细胞-自然杀伤（NK）细胞-通过ADCC杀死肿瘤。为了使ARI-4175成为可行的候选药物，它必须与西妥昔单抗相互作用，以在HCT-116模型中产生显著的肿瘤应答，并有免疫作用机制的证据。如果STTR I期研究成功，则将为STTR II期提出IND使能研究和ARI-4175的I期临床试验的启动。